Vanda Pharmaceuticals (VNDA) Cash & Equivalents (2010 - 2026)

Vanda Pharmaceuticals has reported Cash & Equivalents for 17 years, with the latest figure at $54.0 million in Q1 2026.

• Quarterly Cash & Equivalents fell 51.67% year-over-year to $54.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.0 million (down 51.67% YoY) and the FY2025 annual result came in at $84.9 million, down 17.07% from the prior year.
• Cash & Equivalents fell to $54.0 million in Q1 2026 per VNDA's latest filing, from $84.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $354.2 million in Q1 2023 and troughed at $49.4 million in Q3 2022.
• A 5-year average of $115.6 million and a median of $102.3 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents soared 429.19% in 2023, then plunged 64.66% in 2024.
• Over 5 years, Cash & Equivalents stood at $135.0 million in 2022, then grew by 0.59% to $135.8 million in 2023, then retreated by 24.67% to $102.3 million in 2024, then retreated by 17.07% to $84.9 million in 2025, then plunged by 36.32% to $54.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $54.0 million, $84.9 million, and $70.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.